A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)

被引：16

作者：

Blumenschein, G

Ludwig, C

Thomas, G

Tan, E

Fanucchi, M

Santoro, A

Crawford, J

Breton, J

O'Brien, M

Khuri, F

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] St Clara Hosp, Basel, Switzerland

[3] Leicester Royal Infirm, Leicester, Leics, England

[4] Natl Canc Ctr, Singapore, Singapore

[5] Winship Canc Ctr, Atlanta, GA USA

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Ist Clin Humanitas, Rozzano, Italy

[8] Ctr Hosp Gen Belfort, Belfort, France

[9] Royal Marsden Hosp, Sutton, Surrey, England

来源：

关键词：

D O I：

10.1016/S0169-5002(05)80215-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S30 / S30

页数：1